CLVR vs. PHAS, BCEL, GOVX, ARDS, PHIO, BPTSY, ALZN, REVB, NBY, and EVOK
Should you be buying Clever Leaves stock or one of its competitors? The main competitors of Clever Leaves include PhaseBio Pharmaceuticals (PHAS), Atreca (BCEL), GeoVax Labs (GOVX), Aridis Pharmaceuticals (ARDS), Phio Pharmaceuticals (PHIO), Biophytis (BPTSY), Alzamend Neuro (ALZN), Revelation Biosciences (REVB), NovaBay Pharmaceuticals (NBY), and Evoke Pharma (EVOK). These companies are all part of the "pharmaceutical preparations" industry.
Clever Leaves (NASDAQ:CLVR) and PhaseBio Pharmaceuticals (NASDAQ:PHAS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
PhaseBio Pharmaceuticals received 105 more outperform votes than Clever Leaves when rated by MarketBeat users. However, 81.25% of users gave Clever Leaves an outperform vote while only 61.78% of users gave PhaseBio Pharmaceuticals an outperform vote.
Clever Leaves has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, PhaseBio Pharmaceuticals has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
Clever Leaves has higher revenue and earnings than PhaseBio Pharmaceuticals. Clever Leaves is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Clever Leaves has a net margin of -102.77% compared to PhaseBio Pharmaceuticals' net margin of -12,572.13%. PhaseBio Pharmaceuticals' return on equity of 0.00% beat Clever Leaves' return on equity.
In the previous week, Clever Leaves had 1 more articles in the media than PhaseBio Pharmaceuticals. MarketBeat recorded 2 mentions for Clever Leaves and 1 mentions for PhaseBio Pharmaceuticals. Clever Leaves' average media sentiment score of 0.94 beat PhaseBio Pharmaceuticals' score of 0.00 indicating that Clever Leaves is being referred to more favorably in the media.
6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 9.9% of PhaseBio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Clever Leaves and PhaseBio Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get Clever Leaves News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clever Leaves Competitors List
Related Companies and Tools
